You have 3 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

123I-metaiodobenzylguanidine

Showing 1 - 25 of 4,017
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ventricular Tachycardia, Arrhythmia Trial in Baltimore (123I-metaiodobenzylguanidine)

Completed
Has Results
  • Ventricular Tachycardia
  • Arrhythmia
  • 123I-metaiodobenzylguanidine
  • Baltimore, Maryland
    University of Maryland Medical Center, EP Lab, Rm. N3W77
Jan 25, 2022

Use of MIBG Scan Images in PVC Ablations

Completed
  • Premature Ventricular Contractions
  • MIBG nuclear scan
  • Baltimore, Maryland
    University of Maryland Medical Center
Jan 25, 2022

Neuroendocrine Tumors Trial in Ann Arbor (3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron

Recruiting
  • Neuroendocrine Tumors
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Dec 16, 2021

Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR

Recruiting
  • Ischemic Heart Disease
  • +5 more
  • Cardiovascular Magnetic Resonance Imaging with Exercise Bike
  • +3 more
  • Singapore, Singapore
  • +1 more
May 31, 2021

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT

Terminated
  • Pheochromocytoma
  • Paraganglioma
  • F-18 FDOPA PET/CT
  • Seoul, Songpa-gu, Korea, Republic of
    Asan Medical Center
Jul 13, 2023

Neuroblastoma, Childhood Metastatic Pheochromocytoma Trial in Philadelphia (131 I-Metaiodobenzylguanidine (131 I-MIBG), 131

Available
  • Neuroblastoma
  • Childhood Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131 I-MIBG)
  • 131 I-MIBG
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jul 11, 2022

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

No longer available
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine
  • +2 more
  • Dallas, Texas
    The University of Texas Southwestern Medical Center
Apr 13, 2022

Parkinson Disease, Dementia With Lewy Bodies, MSA - Multiple System Atrophy Trial in Leuven, Gent ([18F]-MFBG PET CT,

Not yet recruiting
  • Parkinson Disease
  • +3 more
  • [18F]-MFBG PET CT
  • +3 more
  • Leuven, Vlaams-Brabant, Belgium
  • +1 more
Oct 31, 2023

123 I-FP-CIT SPECT Prescriptions for Parkinsonian Syndromes

Completed
  • Parkinson
    • Bobigny, France
      Hôpital Avicenne
    Jan 16, 2023

    Neuroblastoma Trial in Copenhagen (18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT))

    Recruiting
    • Neuroblastoma
    • 18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
    • Copenhagen, Denmark
      Rigshospitalet, Copenhagen University Hospital
    Apr 11, 2023

    Lewy Body Disease, Dementia, Parkinsonism Trial in Rochester (meta-iodobenzylguanidine (MIBG) (123I), 123I-MIBG scintigraphy)

    Enrolling by invitation
    • Lewy Body Disease
    • +4 more
    • meta-iodobenzylguanidine (MIBG) (123I)
    • 123I-MIBG scintigraphy
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Aug 23, 2022

    Healthy Subjects (HS) Trial in Huangpu (DaTSCAN™ Ioflupane (123I) Injection)

    Completed
    • Healthy Subjects (HS)
    • DaTSCAN™ Ioflupane (123I) Injection
    • Huangpu, Shanghai, China
      Rujin hospital, affiliated to Shanghai Jiaotong University, Scho
    Jun 20, 2022

    Neuroendocrine Tumors Trial in São Paulo (MIBG-I131)

    Withdrawn
    • Neuroendocrine Tumors
    • MIBG-I131
    • São Paulo, SP, Brazil
      AC Camargo Cancer Center
    May 13, 2022

    Lung Cancer Trial (TILT-123, Pembrolizumab)

    Not yet recruiting
    • Lung Cancer
    • TILT-123
    • Pembrolizumab
    • (no location specified)
    Nov 5, 2023

    Parkinson Disease, Essential Tremor Trial in Clermont-Ferrand, Nîmes, Toulouse (SPECT, PET)

    Recruiting
    • Parkinson Disease
    • Essential Tremor
    • Clermont-Ferrand, France
    • +2 more
    Aug 19, 2022

    Radioiodine Planar andSPECT/CT Imaging With Iodine-123 for

    Recruiting
    • Thyroid Gland Follicular Carcinoma
    • Computed Tomography
    • +3 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Neuroblastoma Trial in San Francisco (124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added),

    Terminated
    • Neuroblastoma
    • 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added)
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    May 12, 2021

    Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA) Trial in China (DaTSCAN™ Ioflupane (123I) Injection)

    Completed
    • Parkinsonian Syndrome
    • +3 more
    • DaTSCAN™ Ioflupane (123I) Injection
    • Beijing, Chaoyang District, China
    • +9 more
    Jun 20, 2022

    Neuroblastoma Trial in United States (131I-MIBG, Dinutuximab, Vorinostat)

    Recruiting
    • Neuroblastoma
    • 131I-MIBG
    • +4 more
    • Los Angeles, California
    • +11 more
    Jan 30, 2023

    Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Minneapolis (131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium

    Recruiting
    • Relapsed Neuroblastoma
    • Metastatic Pheochromocytoma
    • 131 I-Metaiodobenzylguanidine (131I-MIBG)
    • +3 more
    • Minneapolis, Minnesota
      University of Minnesota Masonic Cancer Center
    Jan 20, 2022

    Glioma, Childhood Brainstem, Neuroblastoma Trial in San Francisco, Boston (External beam radiotherapy,

    Not yet recruiting
    • Glioma, Childhood Brainstem
    • Neuroblastoma
    • External beam radiotherapy
    • 131I-Metaiodobenzylguanidine (MIBG)
    • San Francisco, California
    • +1 more
    Aug 17, 2023

    Parkinson Disease, Movement Disorders Trial (Altropane (123I) Injection)

    Not yet recruiting
    • Parkinson Disease
    • Movement Disorders
    • Altropane (123I) Injection
    • (no location specified)
    Nov 23, 2022

    Parkinson Disease Trial in New Haven ([123I]ß-CIT and SPECT imaging, [123I]ß-CIT)

    Active, not recruiting
    • Parkinson Disease
    • New Haven, Connecticut
      Institute for Neurodegenerative Disorders
    Mar 28, 2022

    Neuroblastoma Trial in Montréal, Sherbrooke (Radiopharmaceutical 68Ga-DOTATATE)

    Recruiting
    • Neuroblastoma
    • Radiopharmaceutical 68Ga-DOTATATE
    • Montréal, Quebec, Canada
    • +2 more
    Jan 3, 2023